Adverum Biotechnologies

182 articles about Adverum Biotechnologies

• Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

  3/18/2024

  Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year 2023.

• Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference

  2/28/2024

  Adverum Biotechnologies, Inc. announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in the Ophthalmology Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5th, 2024 at 9:10 a.m. ET.

• Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

  2/12/2024

  Adverum Biotechnologies, Inc. today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13th , 2024 at 12:00 p.m. ET.

• Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD

  2/8/2024

  Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced preliminary safety and efficacy data from the ongoing LUNA Phase 2 trial in patients with wet age-related macular degeneration (AMD).

• Adverum Biotechnologies Announces $127.5 Million Private Placement Financing

  2/5/2024

  Adverum Biotechnologies, Inc. today announced that it has agreed to sell approximately 106.25 million shares of its common stock (or pre-funded warrants in lieu thereof) to a select group of institutional and accredited healthcare specialist investors in a private placement, at a price per share of $1.20, representing a premium of approximately 20% to Adverum’s 30-day volume-weighted average price.

• Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024

  2/1/2024

  Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the company will host a webcast to review preliminary efficacy and safety data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) on Thursday, February 8th, 2024 at 8:00am ET.

• Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer

  1/29/2024

  Adverum Biotechnologies, Inc. today announced that Romuald “Romu” Corbau, Ph.D., has joined Adverum as the company’s chief scientific officer.

• Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society

  12/7/2023

  Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the initial LUNA preliminary efficacy and safety data will be presented at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024.

• Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference

  11/28/2023

  Adverum Biotechnologies, Inc. announced that Linda Rubinstein, chief financial officer, and Star Seyedkazemi, chief development officer of Adverum Biotechnologies, will participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conference on Wednesday, November 29, 2023 at 3:50 p.m. ET in Miami, Florida.

• Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights

  11/9/2023

  Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the third quarter ended September 30, 2023.

• Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of Directors

  11/6/2023

  Adverum Biotechnologies, Inc. today announced the appointment of C. David Nicholson, Ph.D., as an independent member of its Board of Directors, effective November 3, 2023.

• Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023

  11/4/2023

  Adverum Biotechnologies, Inc. announced updated data from the OPTIC extension study of patients with wet AMD during the Retina Subspecialty Day at the American Academy of Ophthalmology 2023 Annual Meeting in San Francisco, California.

• Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial

  9/26/2023

  Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced initial aflibercept protein expression data from its ongoing Phase 2 LUNA trial evaluating ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD).

• Adverum Biotechnologies to Participate in Upcoming Investor Conferences - September 21, 2023

  9/21/2023

  Adverum Biotechnologies, Inc., a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, announced that Adverum Biotechnologies will present at the following upcoming investor conferences.

• Adverum Biotechnologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

  9/5/2023

  Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that Linda Rubinstein, chief financial officer of Adverum Biotechnologies, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023.

• Adverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology Officer

  8/21/2023

  Adverum Biotechnologies, Inc. announced that R. Andrew “Andy” Ramelmeier, Ph.D., has joined Adverum as the company’s chief technology officer.

• Adverum Biotechnologies to Participate in the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

  8/14/2023

  Adverum Biotechnologies, Inc. today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference on Wednesday, August 16, 2023.

• Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results

  8/10/2023

  Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today provided an update on its ongoing Phase 2 LUNA trial evaluating ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) and reported financial results for the second quarter ended June 30, 2023.

• Adverum Biotechnologies Grants License to Ray Therapeutics Inc. for the AAV.7m8 Intravitreal Capsid

  6/12/2023

  Adverum Biotechnologies, Inc. announces an agreement granting Ray Therapeutics a non-exclusive, royalty bearing license of Adverum’s proprietary AAV.7m8 intravitreal vector capsid to be used in conjunction with Ray’s optogenetics payload.

• Adverum Biotechnologies to Participate in the Jefferies Healthcare Conference

  6/2/2023

  Adverum Biotechnologies, Inc. today announced that Laurent Fischer, M.D., president and chief executive officer will present at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 10:00 a.m. ET in New York, New York.